Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an antibody discovery, option and license agreement with Bayer.

Under the terms of the agreement, Twist Biopharma Solutions, a division of Twist Bioscience, will leverage its Library of Libraries to conduct antibody discovery campaigns against targets to be determined by Bayer. Bayer will have the option to license antibodies discovered under the collaboration.

“Our ongoing partnership with Bayer leverages the full suite of our Twist Biopharma Solutions offering of antibody discovery services to identify the best antibodies for Bayer’s specific targets,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By combining the scientific and technical strengths of each organization, and importantly the level of mutual trust built over several years working together, we look forward to identifying and developing new therapies in multiple disease areas to positively impact patients who need it the most.”

Under the terms of the agreement, Twist will receive payments connected with the initiation of research and will be eligible to receive fees associated with research milestones and the exercise of licensing options.

The antibody leads discovered under the collaboration that enter clinical development qualify for certain success-based clinical and commercial milestone payments as well as royalties from product sales. In total, Twist is eligible to receive up to $188 million in clinical and commercial milestone payments plus royalties. In return, Bayer receives exclusive rights to license the antibodies for commercialization in all global territories.